ABOUT US

The Aurinia logo is a modern representation of the lotus flower, a symbol of life and health. Like the lotus, we are resilient in our efforts to develop breakthrough treatments that become the gold standard of patient care, enabling patients to live their fullest lives.

At Aurinia, we embrace the possibility to change the trajectory of autoimmune diseases with unmet medical needs. Our mission and vision are our North Star, directing all that we do to help patients thrive. Our shared values support our mission and vision and guide our behavior and how we work together.

OUR STORY

From its inception, Aurinia has been driven to transform the lives of people living with autoimmune diseases.

Our founders understood the urgency of developing solutions for patients suffering from lupus nephritis. Working tirelessly, they assembled a team of passionate individuals with expertise in drug research, development and commercialization, and sought like-minded partners to enable the delivery of transformative treatments to as many patients as possible, as soon as possible.

This entrepreneurial energy continues to fuel our commitment to changing the trajectory of autoimmune disease and our drive to ensure health equity for all patients.

2013

Aurinia and Isotechnika merge to create Aurinia Pharmaceuticals

2014

Aurinia opens on NASDAQ as AUPH

2016

Aurinia receives FDA Fast Track designation for voclosporin for lupus nephritis

APRIL 2019

Peter Greenleaf is named Chief Executive Officer

DEC 2019

Aurinia announces results from its AURORA 1 Phase III clinical study of voclosporin demonstrating superiority over standard of care

MAR 2020

Aurinia opens U.S. headquarters in Rockville, Maryland

DEC 2020

Aurinia announces collaboration with Otsuka for the development and commercialization of voclosporin in Europe and Japan

JAN 2021

FDA approves LUPKYNIS® (voclosporin) in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).

MAY 2021

Pivotal AURORA 1 Phase III study results published in The Lancet

AUG 2021

Aurinia acquires two preclinical autoimmune assets – today known as AUR200 and AUR300

SEPT 2022

The European Union approves LUPKYNIS in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

NOV 2022

The United Kingdom approved LUPKYNIS in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

APRIL 2023

Switzerland approved LUPKYNIS in combination with a background immunosuppressive therapy for the treatment of adult patients with active class III, IV, or V (including mixed classes III/V and IV/V) lupus nephritis

Management Team

Committed to changing the trajectory of autoimmune diseases, our leaders bring decades of experience in scientific innovation, drug development and commercialization, and corporate strategy.

Peter Greenleaf

Chief Executive Officer

Max Donley

Chief Operating Officer

Dr. Greg Keenan

Chief Medical Officer

Joe Miller

Chief Financial Officer

Stephen Robertson

Executive Vice President, General Counsel

Prem Ramiya

Senior Vice President, Manufacturing & Supply Chain

Andrea Christopher

Executive Director, Corporate Communications & Investor Relations

Board of Directors

Kevin Tang

Director, Chair of the Board and Chair of the Governance Committee

Jeffrey A. Bailey

Director, Chair of the Compensation Committee

Kathy Goetz

Director

Peter Greenleaf

Director, President and CEO

Craig Johnson

Director, Chair of the Audit Committee

Tina S. Nova

Director

OUR PARTNERS

Creating meaningful change requires the efforts of many. Collaboration powers success and we are committed to forging strategic partnerships that advance our mission. We are proud to partner with recognized global leaders in academia, research, and industry to deliver transformative treatment options and improve access for those living with autoimmune diseases. 

For inquiries related to strategic partnerships, please contact us at bd@auriniapharma.com. 

In 2020, Aurinia entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin in the European Union and Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Lichtenstein and Ukraine.

Today, we are actively partnering with Otsuka to commercialize LUPKYNIS® in the EU and the UK.

AWARDS AND RECOGNITION

Aurinia is proud to be part of the healthcare community working to support patients and providers in the autoimmune disease space. We are honored to have been recognized for our leadership by both healthcare industry experts and community leaders. 

LUPKYNIS: Finalist for Best Pharmaceutical Agent
Prix Galien USA, October 2022 

Fastest Growing Companies in British Columbia
Business in Vancouver, August 2022 

Deal of the Year
LifeSciences BC, Sept 2021 

VC Regional Impact Award for Western Canada
CVCA, June 2020 

Company of the Year
LifeSciences BC, February 2018 

National Corporate Visionary Award
Lupus Foundation of America, October 2017

© Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top